Esperion Therapeutics reported $9.66M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Alnylam Pharmaceuticals ALNY:US $ 184.01M 6.38M
Amarin AMRN:US $ 58.63M 13.76M
Amgen AMGN:US $ 5084M 407M
Biogen BIIB:US $ 2105.1M 327.2M
Biomarin Pharmaceutical BMRN:US $ 410.67M 8.28M
Daiichi Sankyo 4568:JP Y 205519M 60424M
Eli Lilly And LLY:US $ 5057.5M 680.4M
Esperion Therapeutics ESPR:US $ 9.66M 2.05M
Halozyme Therapeutics HALO:US $ 118.42M 17.07M
Intercept Pharmaceuticals ICPT:US $ 71.45M 16.38M
Intra Cellular Therapies ITCI:US $ 50.93M 19.09M
IONIS PHARMACEUT IONS:US $ 129.05M 8.7M
Merk MRK:US $ 10895M 328M
Moderna Inc MRNA:US 3.37B 1.68B
Nektar Therapeutics NKTR:US $ 16.47M 3.04M
Pfizer PFE:US $ 19071M 3420M
Ptc Therapeutics PTCT:US $ 155.89M 17.29M
Puma Biotechnology PBYI:US $ 44.6M 9.71M
Regeneron Pharmaceuticals REGN:US $ 2560.1M 0.1M
Sarepta Therapeutics SRPT:US $ 195.69M 16.3M
Seattle Genetics SGEN:US $ 391.4M 52.57M
United Therapeutics UTHR:US $ 437.2M 1.2M